Expert Analysis

Update on Investigational Agents in HCV: 2007

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Update on Investigational Agents in HCV: 2007

Faculty:
Nezam H. Afdhal, MD, FRCPI Ira M. Jacobson, MD David R. Nelson, MD

CME CREDIT INFORMATION

Release Date: 01/07/08

Expiration Date: 01/06/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe data regarding the safety and efficacy of novel therapies for HCV
Discuss recent studies regarding the development of resistance during treatment with novel HCV therapies
Explain the latest data on the optimal treatment duration for HCV therapies in development

Topics covered include:

Clinical Studies of the Investigational Protease Inhibitor Telaprevir
Efficacy, Safety, and Resistance Analysis With R1626
Treatment With R7128 in Previous Nonresponders
Clinical Studies With NS5B Polymerase Inhibitors VCH-759 and GS-9190
Anti-HCV Activity Observed With Nitazoxanide
Albinterferon Alfa-2b in Treatment-Naive or -Experienced Patients
Phase IIa Trial of Controlled-Release Recombinant Interferon Alfa-2b
Anti-HCV Activity With GI-5005, a Yeast-Based Immunotherapy
Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.